

SUPPLEMENTARY TABLES S1 and S2

Supplementary Table S1

Serum theophylline levels in each of the three study arms in the ITT population at baseline, 12 weeks and 48 weeks

Theophylline (mg/L)	Placebo (N=554)	Low-dose Theophylline + placebo (N=568)	Low-dose Theophylline + Low dose oral Prednisone (N=548)
Baseline			
N	23	28	24
Mean (SD)	0.8 (2.1)	1.3 (2.2)	3.5 (5.0)
Median (Q1; Q3)	0.1 (0.0; 0.1)	0.1 (0.0; 1.2)	1.2 (0.0; 5.0)
Min, max	0, 8	0, 8	0, 19
Week 12			
N	22	25	24
Mean (SD)	0.7 (2.0)	2.5 (3.0)	4.4 (5.7)
Median (Q1; Q3)	0.1 (0.0; 0.1)	1.1 (0.1; 3.6)	2.1 (0.1; 6.9)
Min, max	0, 9	0, 10	0, 20
Week 48			
N	21	24	24
Mean (SD)	0.7 (2.0)	3.1 (2.9)	4.8 (5.2)
Median (Q1; Q3)	0.0 (0.0; 0.1)	2.6 (0.1; 5.0)	3.7 (0.9; 6.3)
Min, max	0, 7	0, 11	0, 20

Supplementary Table S2

Cortisol measurements at Week 50 in sub-sample of participants in ITT population

Cortisol assessment	Placebo (N=554)	Low-dose Theophylline + placebo (N=568)	Low-dose Theophylline + Low dose Prednisone (N=548)
Participants in cortisol testing subgroup	31 (5.5%)	30 (5.3%)	30 (5.5%)
S. cortisol Week 50 (n)	31	30	30
Mean (SD) S.cortisol	266.6 (138.5)	266.4 (139.9)	180.6 (105.5)
Median (Q1; Q3)	256.8 (153.2; 367.2)	245.0 (197.8; 342.9)	184.5 (88.2; 242.1)
Min Max	12, 588	47, 727	18, 468